Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs

This article was originally published in PharmAsia News

Executive Summary

Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.

Advertisement

Related Content

Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure
Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Gilead Fights For Viread Patent And Royalties In India
China’s Amended Patent Law Could Facilitate Compulsory Licenses Of Pharmaceuticals – Patent Attorneys

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC081374

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel